Protein therapy for metastatic breast cancer
Part of Cancer, Skin clinical trials.
This study tests a new medication called GcMAF (a type of protein therapy) for people with advanced breast cancer that has spread. It may help your immune system fight the cancer, and you might receive either the study drug or a placebo (a pill with no active medicine).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have breast cancer that has spread to other parts of the body (metastatic).
- You need to have already tried at least one type of treatment for the metastatic cancer, such as chemo or hormone therapy.
- You must be a woman aged 18 to 70.
- Your doctor should expect you to live at least 6 more months.
- You must not have any other active cancer (except for some minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests whether immune cells taken from your own tumor (called tumor-infiltrating lymphocytes) can be grown in a lab and given back to you to fight the cancer. It is for people with advanced breast cancer who have exhausted standard treatment options.
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.